Factor VII Active Protein | F7 active protein

Factor VII Protein, Mouse, Recombinant (His Tag)

Cat. Num. AAA8122485

• Gene Names: F7; Cf7; FVII; mfVII; AI132620
• Purity: >90% as determined by SDS-PAGE
• Synonyms: Factor VII; Factor VII Protein; Mouse; Recombinant (His Tag); Mouse Coagulation Factor VII/FVII/F7 Protein (His Tag); AI132620 Protein; Cf7 Protein; FVII Protein; coagulation factor VII (serum prothrombin conversion accelerator); F7 active protein

• Host: CHO Stable Cells
• Purity/Purification: >90% as determined by SDS-PAGE
• Form/Format: Lyophilized from sterile PBS, pH7.4. Normally 5%-8% trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
• Sequence: Met1-Leu446

• Species: Mouse
• Endotoxin: <1.0EU per ug of the protein as determined by the LAL method
• Predicted N Terminal: Val 25 & Ala 42
• Tag: C-His
• Protein Construction: A DNA sequence encoding the mouse FVII (NP_034302.2)(Met 1-Leu 446) was fused with the a polyhistidine tag at the C-terminus.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
• Activity: Measured by its binding ability in a functional ELISA. Immobilized mouse F7-his at 10ug/ml (100uL/well) can bind biotinylated mouse F3-his. The EC50 of biotinylated mouse F3-his is 0.1-0.3ug/ml.
• Preparation and Storage: Samples are stable for up to twelve months from date of receipt at -20 degree C to -80 degree C. Store it under sterile conditions at -20 degree C to -80 degree C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.; In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid.; They are shipped out with blue ice.

SDS-Page

Testing Data

(Measured by its binding ability in a functional ELISA. Immobilized mouse F7-his at 10 ug/ml (100 ul/well) can bind biotinylated mouse F3-his. The EC50 of biotinylated mouse F3-his is 0.1-0.3 ug/ml.)

Related Product Information for F7 active protein

Background: Coagulation factor VII, also known as Serum prothrombin conversion accelerator, Factor VII, F7 and FVII, is a member of the peptidase S1 family. Factor VII is one of the central proteins in the coagulation cascade. It is an enzyme of the serine protease class, and Factor VII (FVII) deficiency is the most frequent among rare congenital bleeding disorders. Factor VII contains two EGF-like domains, one Gla (gamma-carboxy-glutamate) domain and one peptidase S1 domain. The main role of factor VII is to initiate the process of coagulation in conjunction with tissue factor (TF). Tissue factor is found on the outside of blood vessels, normally not exposed to the blood stream. The action of the Factor VII is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent and is produced in the liver. Upon vessel injury, tissue factor is exposed to the blood and circulating Factor VII. Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), factor Xa, IXa, XIIa, and the FVIIa-TF complex itself. Recombinant activated factor VII (rFVIIa) is a haemostatic agent, which was originally developed for the treatment of haemophilia patients with inhibitors against factor FVIII or FIX. FVIIa binds specifically to endothelial protein C receptor (EPCR), a known cellular receptor for protein C and activated protein C, on the endothelium. rFVIIa is a novel hemostatic agent, originally developed for the treatment of hemorrhage in hemophiliacs with inhibitors, which has been successfully used recently in an increasing number of nonhemophilic bleeding conditions.

Product Categories/Family for F7 active protein

Serine Proteases and Regulators

References

Franchini M, et al. (2007) Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis. 18(7): 589-93.Lapecorella M, et al. (2008) Factor VII deficiency: defining the clinical picture and optimizing therapeutic options. Haemophilia. 14(6): 1170-5.Grottke O, et al. (2010) Activated recombinant factor VII (rFVIIa). Best Pract Res Clin Anaesthesiol. 24(1): 95-106.

NCBI and Uniprot Product Information

• NCBI GI #: 225543550
• NCBI GeneID: 14068
• NCBI Accession #: NP_034302.2
• NCBI GenBank Nucleotide #: NM_010172.3
• UniProt Accession #: P70375; Q61109
• Molecular Weight: 160,000
• NCBI Official Full Name: coagulation factor VII
• NCBI Official Synonym Full Names: coagulation factor VII
• NCBI Official Symbol: F7
• NCBI Official Synonym Symbols: Cf7; FVII; mfVII; AI132620
• NCBI Protein Information: coagulation factor VII; serum prothrombin conversion accelerator
• UniProt Protein Name: Coagulation factor VII
• Protein Family: Factor VIII intron 22 protein
• UniProt Gene Name: F7
• UniProt Synonym Gene Names: Cf7
• UniProt Entry Name: FA7_MOUSE

NCBI Description

This gene encodes a vitamin K-dependent serine protease that plays a critical role in the extrinsic pathway of blood coagulation. Upon contact with tissue factor III (TF III), the encoded protein forms an activated complex termed TF-FVIIa that initiates the coagulation cascade involving other coagulation factors, ultimately resulting in a fibrin clot. Complete lack of the encoded protein in mice results in in perinatal lethality due to bleeding from normal blood vessels. [provided by RefSeq, Apr 2015]

Uniprot Description

F7: Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium. Defects in F7 are the cause of factor VII deficiency (FA7D). A hemorrhagic disease with variable presentation. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or repeated hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Finally, numerous subjects are completely asymptomatic despite very low factor VII levels. Belongs to the peptidase S1 family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Secreted, signal peptide; Protease; EC 3.4.21.21; Motility/polarity/chemotaxis; Apoptosis; Secreted

Cellular Component: extracellular space; extracellular region; vesicle

Molecular Function: peptidase activity; hydrolase activity; serine-type peptidase activity; serine-type endopeptidase activity; endopeptidase activity; calcium ion binding; glycoprotein binding; catalytic activity; receptor binding

Biological Process: positive regulation of protein kinase B signaling cascade; positive regulation of positive chemotaxis; positive regulation of blood coagulation; hemostasis; positive regulation of leukocyte chemotaxis; proteolysis; blood coagulation